文献速递临床试验与 GCP流行病学与生物统计

基于成功概率的肿瘤无缝II/III期试验优化设计

Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS).
PubMed 文献 · Stat Med · 2018-08-06

针对肿瘤药物开发中的无缝II/III期临床试验,现有设计多关注I类错误控制、II期后样本量重估及治疗选择,但如何确定继续/终止边界和II期样本量仍未解决。本文基于成功概率(PoS)讨论如何确定II期和III期样本量及相应继续/终止标准,并扩展方法在II期部分加入中期分析以加速决策。

要点

  • 基于成功概率可确定无缝II/III期试验的II期与III期样本量及继续/终止标准。
  • 在II期部分加入中期分析可加速继续/终止决策。
  • 若疗效显著可缩短总试验时长,若无效可早期终止减少无效暴露。

核心结论

  • 基于成功概率可确定肿瘤无缝II/III期试验的II期与III期样本量及继续/终止标准。

研究设计与样本

  • 方法学研究,讨论基于成功概率确定无缝II/III期肿瘤试验的II期和III期样本量及继续/终止标准,并扩展至II期内含中期分析的设计。

主要发现

  • 在II期部分加入中期分析可加速继续/终止决策;若疗效显著可缩短总试验时长,若无效可早期终止减少无效暴露。

临床怎么用

  • 可用于肿瘤无缝II/III期试验的样本量规划与继续/终止决策,并可通过II期内中期分析加速决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, there has been an increasing trend in conducting seamless phase 2/3 clinical trials for drug development in the pharmaceutical industry due to the visible advantages compared with traditional approaches for separate phase 2 and 3 development. Innovative study designs have been proposed for seamless phase 2/3 trials, which mainly focus on the traditional aspects of study design, such as how to control the Type I error rate, sample size re-estimation after the phase 2 portion, and how to make treatment selection at the end of the phase 2 portion. However, there are still some questions unresolved such as how to determine the go/no-go boundary and how to plan the phase 2 portion sample size. In this paper, we discuss how to determine the phase 2 portion and phase 3 portion sample sizes as well as the corresponding go/no-go criteria for a seamless phase 2/3 oncology trial based on Probability of Success. In addition, we further expand the methodology to include designs with an interim look within the phase 2 portion to speed up the go/no-go decision-making process. In case of overwhelming efficacy, this design would further shorten the overall trial duration. In case of inefficacy, this design can stop the trial earlier without exposing more patients to inefficacious treatment.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Teng Z, Liang L, Liu G, et al. Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS). Stat Med. 2018. PMID: 30084110. doi:10.1002/sim.7910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。